RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation

Archive ouverte

Manchon, Laurent | Chébli, Karim | Papon, Laura | Paul, Conception | Garcel, Aude | Campos, Noëlie | Scherrer, Didier | Ehrlich, Hartmut | Hahne, Michael | Tazi, Jamal

Edité par CCSD ; Nature Publishing Group -

International audience. RNA-Seq enables the generation of extensive transcriptome information providing the capability to characterize transcripts (including alternative isoforms and polymorphism), to quantify expression and to identify differential regulation in a single experiment. To reveal the capacity of new anti-HIV ABX464 candidate in modulating the expression of genes, datasets were generated and validated using RNA-seq approach. This comprehensive dataset will be useful to deepen the comprehensive understanding of the progression of human immunodeficiency virus (HIV) associated with mucosal damage in the gastrointestinal (GI) tract and subsequent inflammation, providing an opportunity to generate new therapies, diagnoses, and preventive strategies.

Suggestions

Du même auteur

The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages

Archive ouverte | Chebli, Karim | CCSD

International audience. The progression of human immunodeficiency virus (HIV) is associated with mucosal damage in the gastrointestinal (GI) tract. This damage enables bacterial translocation from the gut and leads ...

ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases

Archive ouverte | Apolit, Cécile | CCSD

International audience. Advanced therapies have transformed the treatment of inflammatory bowel disease; however, many patients fail to respond, highlighting the need for therapies tailored to the underlying cell an...

Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

Archive ouverte | Vautrin, Audrey | CCSD

International audience. ABX464 is a first-in-class, clinical-stage, small molecule for oral administration that has shown strong anti-inflammatory effects in the DSS-model for inflammatory bowel disease (IBD) and al...

Chargement des enrichissements...